Skip to main content
. 2021 Oct 21;7(1):108–116. doi: 10.1016/j.ekir.2021.10.012

Table 2.

Results of in silico analysis

In vitro
No. Exon Variant
In silico (missense)
In silico
In silico (splicing)
Splicing Nucleotide Amino acid SIFT PolyPhen-2 Mutation taster Align GVGD MaxEntScan
ESS/ESE (count)
HSF EX-SKIP SD-SCORE
WT Mut WT Mut
Aberrant 2 19 c.1165G>A Gly389Arg D (score: 0) Pro (score: 1.000) DC (prob: 1) C25 (GV: 00.00–GD: 55.27) 8.76 4.44 10/23 10/23 Aberrant Normal Aberrant
3 21 c.1423G>A Gly475Ser D (score: 0.01) Pro (score: 1.000) DC (prob: 1) C65 (GV: 60.00–GD: 97.30) 5.13 −3.12 2/62 2/61 Aberrant Normal Aberrant
4 25 c.1948G>T Gly650Cys D (score: 0) Pro (score: 1.000) DC (prob: 1) C65 (GV: 0.00–GD: 158.23) 10.86 8.31 0/25 0/25 Aberrant Normal Aberrant
5 c.1948G>A Gly650Ser D (score: 0) Pro (score: 1.000) DC (prob: 1) C55 (GV: 0.00–GD: 55.27) 10.86 10.08 0/25 0/25 Aberrant Normal Normal
6 28 c.2244G>T Lys748Asn D (score: 0.04) Pro (score: 0.999) DC (prob: 1) C0 (GV: 109.22–GD: 46.95) 3.93 0 13/16 13/16 Aberrant Normal Aberrant
7 30 c.2509G>A Gly837Ser D (score: 0) Pro (score: 0.993) DC (prob: 1) C55 (GV: 0.00–GD: 55.27) 9.45 5.2 16/13 16/11 Aberrant Aberrant Aberrant
8 31 c.2677G>C Gly893Arg D (score: 0) Pro (score: 1.000) DC (prob: 1) C65 (GV: 0.00–GD: 128.13) 8.55 4.34 4/30 4/30 Aberrant Normal Aberrant
9 c.2677G>A Gly893Ser D (score: 0) Pro (score: 1.000) DC (prob: 1) C55 (GV: 0.00–GD: 55.27) 8.55 3.86 4/30 4/30 Aberrant Normal Aberrant
10 32 c.2767G>C Gly923Arg D (score: 0) Pro (score: 1.000) DC (prob: 1) C65 (GV: 0.00–GD: 125.13) 8.49 2.1 8/18 8/17 Aberrant Aberrant Aberrant
12 37 c.3373G>A Gly1125Arg D (score: 0) Pro (score: 1.000) DC (prob: 1) C65 (GV: 0.00–GD: 125.13) 8.59 1.89 10/29 10/29 Aberrant Normal Aberrant
13 41 c.3790G>A Gly1264Arg Tole (score: 0.15) Pro (score: 1.000) DC (prob: 1) C0 (GV: 170.55–GD: 2.75) 9.8 7.44 19/19 19/19 Aberrant Normal Aberrant
14 42 c.3924G>C Gln1308His D (score: 0.02) Pos (score: 0.560) DC (prob: 1) C0 (GV: 75.14–GD: 11.15) 9.79 3.74 0/55 0/55 Aberrant Normal Aberrant
15 43 c.3997G>A Gly1333Ser D (score: 0) Pro (score: 1.000) DC (prob: 1) C55 (GV: 0.00–GD: 55.27) 7.51 1.24 11/14 11/14 Aberrant Normal Aberrant
16 44 c.4069G>C Gly1357Arg D (score: 0) Pro (score: 1.000) DC (prob: 1) C65 (GV: 0.00–GD: 125.13) 10.77 7.45 18/21 18/21 Aberrant Normal Aberrant
17 c.4069G>A Gly1357Ser D (score: 0) Pro (score: 1.000) DC (prob: 1) C55 (GV: 0.00–GD: 55.27) 10.77 7.61 18/21 18/21 Aberrant Normal Aberrant
19 48 c.4688G>A Arg1563Glu D (score: 0) Pro (score: 1.000) DC (prob: 1) C35 (GV: 0.00–GD: 42.81) 10.48 5.2 7/12 7/12 Aberrant Normal Aberrant
20 50 c.4976G>A Ser1659Asn Tole (score: 0.65) Pos (score: 0.953) DC (prob: 1) C0 (GV: 118.33–GD: 0.00) 9.65 2.69 14/19 14/19 Aberrant Normal Aberrant
Normal 1 15 c.891A>T Arg297Ser D (score: 0.04) Pos (score: 0.669) DC (prob: 1) C15 (GV: 97.59–GD: 95.93) 9.35 8.46 5/31 5/29 Aberrant Aberrant Normal
11 35 c.3106G>A Gly1036Arg D (score: 0) Pro (score: 1.000) DC (prob: 1) C65 (GV: 0.00–GD: 125.13) 10.67 9.1 22/24 22/24 Aberrant Normal Aberrant
18 46 c.4297G>A Gly1433Ser D (score: 0) Pro (score: 1.000) DC (prob: 1) C55 (GV: 0.00–GD: 55.27) 10.77 7.61 1/33 1/34 Aberrant Normal Aberrant

D, deleterious; DC, disease casing; ESS, exonic splicing silencer; ESE, exonic splicing enhancer; HSF, human splicing finder; Mut, mutant; No., number; Prob, probably damaging; Pos, possibly damaging; SD-SCORE, SD-SCORE algorithm; Tole, tolerated; WT, wild type.